The relationship between dysbiosis and the development of neurodegenerative disorders: a systematic literature review
DOI:
https://doi.org/10.33448/rsd-v12i5.41454Keywords:
Gastrointestinal Microbiome; Dysbiosis; Central Nervous System; Neurodegenerative diseases.Abstract
Dysbiosis consists of an imbalance between protective and aggressive bacteria in the gastrointestinal tract (GI tract), associated with the production of toxins that can be harmful to health. The impact on the intestinal microbiome can be caused by the indiscriminate use of medications, inadequate diet, immunological disorders, and advancing age. The present work aims to analyze, by comparing 23 studies, how the gut-brain axis is influenced by gastrointestinal bacteria and their modifications when dysbiotic, as well as their participation in the development of neurodegenerative diseases such as Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD) - and to list the advantages of therapies to optimize the prognosis of these diseases. As for AD, the gut microbiota may influence its onset and/or progression, through increased amyloid-beta immunoreactivity and phospho-tau changes; moreover, bacterial secretions stimulate neuroinflammation and neurodegeneration. In ALS, the reduction of bacteroid groups promotes increased abundance of cyanobacteria producing neurotoxic molecules. Regarding PD, studies state that the disease may begin in the intestine through correlation with alpha-synuclein aggregation in the colon. As for therapy, researchers state that dietary modifications and the use of antibiotics and probiotics help rescue the intestinal microbiome and reduce neurodegeneration; it is also highlighted that fecal matter transplantation is neuroprotective by reducing intestinal dysbiosis. It is concluded that neurodegenerative diseases are stimulated by the product of bacteria, which affect the blood-brain barrier and negatively influence the homeostasis of the nervous system.
References
Bello-Medina, P. C., Corona-Cervantes, K., Zavala Torres, N. G., González, A., Pérez-Morales, M., González-Franco, D. A., ... & Pacheco-López, G. (2022). Chronic-antibiotics induced Gut microbiota dysbiosis rescues memory impairment and reduces β-amyloid aggregation in a preclinical Alzheimer’s disease model. International Journal of Molecular Sciences, 23(15), 8209.
Brenner, D., Hiergeist, A., Adis, C., Mayer, B., Gessner, A., Ludolph, A. C., & Weishaupt, J. H. (2018). The fecal microbiome of ALS patients. Neurobiology of aging, 61, 132-137.
Chok, K. C., Ng, K. Y., Koh, R. Y., & Chye, S. M. (2021). Role of the gut microbiome in Alzheimer’s disease. Reviews in the Neurosciences, 32(7), 767-789.
Di Gioia, D., Bozzi Cionci, N., Baffoni, L., Amoruso, A., Pane, M., Mogna, L., ... & Mazzini, L. (2020). A prospective longitudinal study on the microbiota composition in amyotrophic lateral sclerosis. BMC medicine, 18, 1-19.
Favero, F., Barberis, E., Gagliardi, M., Espinoza, S., Contu, L., Gustincich, S., ... & Corazzari, M. (2022). A Metabologenomic approach reveals alterations in the gut microbiota of a mouse model of Alzheimer’s disease. Plos one, 17(8), e0273036.
Galvão, T. F., Pansani, T. D. S. A., & Harrad, D. (2015). Principais itens para relatar Revisões sistemáticas e Meta-análises: A recomendação PRISMA. Epidemiologia e serviços de saúde, 24, 335-342.
Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., ... & Hirayama, M. (2015). Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson’s disease. PloS one, 10(11), e0142164.
Kaur, H., Nagamoto-Combs, K., Golovko, S., Golovko, M. Y., Klug, M. G., & Combs, C. K. (2020). Probiotics ameliorate intestinal pathophysiology in a mouse model of Alzheimer’s disease. Neurobiology of aging, 92, 114-134.
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., ... & Shannon, K. M. (2015). Colonic bacterial composition in Parkinson's disease. Movement Disorders, 30(10), 1351-1360.
Li, B., He, Y., Ma, J., Huang, P., Du, J., Cao, L., ... & Chen, S. (2019). Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota. Alzheimer's & Dementia, 15(10), 1357-1366.
Mazzini, L., Mogna, L., De Marchi, F., Amoruso, A., Pane, M., Aloisio, I., ... & Mogna, G. (2018). Potential role of gut microbiota in ALS pathogenesis and possible novel therapeutic strategies. Journal of clinical gastroenterology, 52, S68-S70.
Perez-Pardo, P., Dodiya, H. B., Engen, P. A., Forsyth, C. B., Huschens, A. M., Shaikh, M., ... & Keshavarzian, A. (2019). Role of TLR4 in the gut-brain axis in Parkinson’s disease: a translational study from men to mice. Gut, 68(5), 829-843.
Perez-Pardo, P., Dodiya, H. B., Engen, P. A., Naqib, A., Forsyth, C. B., Green, S. J., ... & Kraneveld, A. D. (2018). Gut bacterial composition in a mouse model of Parkinson’s disease. Beneficial microbes, 9(5), 799-814.
Rowin, J., Xia, Y., Jung, B., & Sun, J. (2017). Gut inflammation and dysbiosis in human motor neuron disease. Physiological reports, 5(18), e13443.
Rusch, C., Beke, M., Tucciarone, L., Dixon, K., Nieves Jr, C., Mai, V., ... & Langkamp-Henken, B. (2021). Effect of a Mediterranean diet intervention on gastrointestinal function in Parkinson’s disease (the MEDI-PD study): study protocol for a randomised controlled trial. BMJ open, 11(9), e053336.
Srivastav, S., Neupane, S., Bhurtel, S., Katila, N., Maharjan, S., Choi, H., ... & Choi, D. Y. (2019). Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity. The Journal of Nutritional Biochemistry, 69, 73-86.
Sun, J., Zhan, Y., Mariosa, D., Larsson, H., Almqvist, C., Ingre, C., ... & Fang, F. (2019). Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden. European Journal of Neurology, 26(11), 1355-1361.
Sun, M. F., Zhu, Y. L., Zhou, Z. L., Jia, X. B., Xu, Y. D., Yang, Q., ... & Shen, Y. Q. (2018). Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson’s disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain, behavior, and immunity, 70, 48-60.
Vogt, N. M., Kerby, R. L., Dill-McFarland, K. A., Harding, S. J., Merluzzi, A. P., Johnson, S. C., ... & Rey, F. E. (2017). Gut microbiome alterations in Alzheimer’s disease. Scientific reports, 7(1), 13537.
Wang, X., Sun, G., Feng, T., Zhang, J., Huang, X., Wang, T., ... & Geng, M. (2019). Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell research, 29(10), 787-803.
Zeng, Q., Shen, J., Chen, K., Zhou, J., Liao, Q., Lu, K., ... & Bi, F. (2020). The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients. Scientific Reports, 10(1), 12998.
Zhai, C. D., Zheng, J. J., An, B. C., Huang, H. F., & Tan, Z. C. (2019). Intestinal microbiota composition in patients with amyotrophic lateral sclerosis: establishment of bacterial and archaeal communities analyses. Chinese Medical Journal, 132(15), 1815-1822.
Zhang, B., Chen, T., Cao, M., Yuan, C., Reiter, R. J., Zhao, Z., ... & Li, C. (2022). Gut microbiota dysbiosis induced by decreasing endogenous melatonin mediates the pathogenesis of Alzheimer’s disease and obesity. Frontiers in immunology, 13.
Zhang, Y. G., Wu, S., Yi, J., Xia, Y., Jin, D., Zhou, J., & Sun, J. (2017). Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clinical therapeutics, 39(2), 322-336.
Zhang, Y., Ogbu, D., Garrett, S., Xia, Y., & Sun, J. (2021). Aberrant enteric neuromuscular system and dysbiosis in amyotrophic lateral sclerosis. Gut Microbes, 13(1), 1996848.
Zhou, Y., Wang, Y., Quan, M., Zhao, H., & Jia, J. (2021). Gut microbiota changes and their correlation with cognitive and neuropsychiatric symptoms in Alzheimer’s disease. Journal of Alzheimer's Disease, 81(2), 583-595.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Juliana de Castro Vilanova; Beatriz Ribas de Melo; Thaiz Helena Lopes da Rocha; Iane Lopes da Rocha; Bruno Mendes Moura Dias Guerra; Tereza Cristina Carvalho de Sousa Garcês; Ana Rachel Oliveira de Andrade
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
